GlassScriptPhysician profile
Vipul J Patel
NPI 1235329111
$1,436.24
in general payments reported to CMS, 2019-2025
21 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $200 · 2021: $14.69 · 2022: $136 · 2023: $168 · 2024: $387 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $197.06 | 2024-2025 | |
| Pfizer INC. | $165.95 | 2019-2024 | |
| Paragonix Technologies, INC. | $160.04 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.03 | 2023 | Livtencity |
| Astellas Pharma US INC | $124.96 | 2020 | |
| Abiomed | $119.94 | 2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $102.89 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $88.78 | 2019-2025 | Amvuttra |
| Teleflex LLC | $59.76 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.74 | 2019-2021 | |
| Gilead Sciences, INC. | $38.65 | 2019-2023 | Trodelvy |
| Abbott Laboratories | $29.01 | 2020 | |
| Amgen INC. | $26.81 | 2019-2020 | |
| Assertio Therapeutics, INC. | $18.96 | 2020 | |
| Atricure, INC. | $18.38 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15.00 | 2019 | |
| Akcea Therapeutics, INC. | $14.87 | 2019 | |
| Insmed, INC. | $14.33 | 2019 | |
| Amarin Pharma, INC. | $14.04 | 2019 | |
| Shire North American Group INC | $13.13 | 2019 | |
| Glaxosmithkline, LLC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vipul Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.